View Older Stories View More Recent Stories
-
Morgan Stanley Downgrades Novo Nordisk (NVO) to Underweight
-
Morgan Stanley Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Underweight
-
EU will still have 15% pharma tariff, not 100% - Bloomberg
-
Novo Nordisk: Diabetes and obesity GLP-1 portfolio still attractive says Bernstein
-
UBS slashes global GLP-1 sales estimate for 2030 on softer outlook
-
Walmart (WMT) Adds Home Delivery for Ozempic, Other Refrigerated Drugs - Bloomberg
-
Trump: tariffs will get countries to agree to drug pricing plan
-
Novo Nordisk Cuts U.S. Obesity Education Team As Layoffs Begin, Say Sources, Online Posts - Reuters
-
BMO Capital on Novo Nordisk (NVO): 'still give the competitive edge to Lilly following this week'
-
UBS Reiterates Neutral Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Novo Nordisk (NVO) call put ratio 3.2 calls to 1 put into share price up before the bell
-
Novo Nordisk's oral weight loss pill shows 16.6% weight loss in trial
-
Berenberg Upgrades Novo Nordisk (NOVOB:DC) (NVO) to Buy
-
Novo Nordisk (NVO) issued warning letter by FDA over misleading Wegovy promotion
-
FDA issues warning letter to Novo Nordisk over misleading drug promotion
-
How are GLP-1 drugs changing U.S. grocery behavior?
-
Novo Nordisk's Wegovy may quiet thoughts about food, study shows; shares up
-
Rothschild Redburn Upgrades Novo Nordisk (NVO) to Buy
-
Novo Nordisk receives EU approval for cardiovascular benefits of oral semaglutide
-
Novo Nordisk (NVO) stock: Barclays breaks down key investor questions and debates
-
BMO Capital on Novo Nordisk (NVO): 'New CEO Doustdar Implements Massive Restructuring'
-
Novo Nordisk to cut 9,000 jobs in major restructuring
-
Bernstein SocGen Group Upgrades Novo Nordisk (NOVOB:DC) (NVO) to Outperform
-
Truist Securities Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
Novo Nordisk (NVO) PT Lowered to $70 at TD Cowen
-
Novo Nordisk, Eli Lilly rise after Viking obesity trial data
-
Novo Nordisk's Ozempic gets Canadian approval for kidney disease
-
Mizuho Reiterates Neutral Rating on GoodRx Holdings Inc. (GDRX)
-
Goldman Sachs Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)
-
BofA Securities Reiterates Underperform Rating on GoodRx Holdings Inc. (GDRX)
-
Active options: NVO BBAI CRWV MSTR AMZN BULL FSLR NIO GOOGL
-
GoodRx partners with Novo Nordisk to offer Ozempic, Wegovy for $499 monthly
-
Novo Nordisk (NVO) launches cash-pay Ozempic at $499/month, half the regular price
-
Novo Nordisk offers Ozempic at $499 monthly for uninsured patients
-
BMO Capital: 'Novo Nordisk (NVO) Takes a Step in the Right Direction'
-
BNP Paribas Exane Upgrades Novo Nordisk (NOVOB:DC) (NVO) to Neutral
-
What to do with Novo Nordisk shares after recent volatility? Barclays explains
-
Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY)
-
Novo shares rise for second day after Lilly obesity pills trails Wegovy in trial
-
Novo Nordisk (NVO) call put ratio 2.3 calls to 1 put with a focus on August calls
-
Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK355 at HSBC
-
Eli Lilly shares slip 7% premarket as weight-loss pill study overshadows earnings
-
BofA Securities Reiterates Neutral Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Novo Nordisk shares jump as Eli Lilly obesity pill disappoints
-
Novo Nordisk (NVO) PT Lowered to $50 at BMO Capital
-
Morgan Stanley Reiterates Overweight Rating on Akero Therapeutics (AKRO) (premarket)
-
Stocks expected to have increasing option volume: NVO LCID RNG DIS CPNG RIVN ABNB MCD DIS UBER SHOP ROK GPN DT U PLNT
-
Novo Nordisk (NVO) Reports 1H EPS of DKK12.49
-
Novo Nordisk earnings preview: Analysts cautious ahead of release
-
Novo Nordisk files 14 new lawsuits over compounded semaglutide drugs

